VBI hepatitis B vaccine meets main goals in late-stage trial
June 17 (Reuters) - VBI Vaccines Inc VBIV.O said on Monday a late-stage study testing its hepatitis B vaccine met its main goals.
The trial tested VBI's Sci-B-Vac against GlaxoSmithKline's GSK.L's Engerix-B vaccine, which was first approved in the United States in 1989.
(Reporting by Tamara Mathias in Bengaluru; Editing by Shailesh Kuber)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.